Lupin Limited is a pharmaceutical company headquartered in Mumbai, India. The company was founded in 1968 and has operations in over 100 countries. Lupin is primarily engaged in the development, manufacture, and marketing of generic and branded pharmaceuticals, biosimilars, and specialty pharmaceuticals.<\/p>\n
The company has a diversified portfolio of products across therapeutic areas such as cardiovascular, diabetes, respiratory, central nervous system, gastroenterology, and women’s health. Lupin has a strong focus on research and development, with significant investments in developing innovative products and drug delivery technologies. In terms of earnings, Revenue from Operations for Q3 FY23 was \u20b94,244.56 crore, a 4% increase from \u20b94,087.48 crore in the same period last year. The third quarter\u2019s other income, which contributed \u20b977.66 Crore to the Total Revenue. Meanwhile, the Profit Before Tax improved to \u20b9246.14 Crore from \u20b9167 Crore from the same quarter previous year. The Consolidated Net Profit was \u20b9157.65 crore, significantly down from \u20b9549 crore in the same quarter last year. This quarter\u2019s earnings per share was \u20b93.36.<\/p>\n","protected":false},"excerpt":{"rendered":"
Lupin Limited is a pharmaceutical company headquartered in Mumbai, India. The company was founded in 1968 and has operations in over 100 countries. Lupin is primarily engaged in the development, manufacture, and marketing of generic and branded pharmaceuticals, biosimilars, and specialty pharmaceuticals. The company has a diversified portfolio of products across therapeutic areas such as […]<\/p>\n","protected":false},"author":1917,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392],"tags":[1115],"class_list":["post-143124","post","type-post","status-publish","format-standard","hentry","category-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":145655,"url":"https:\/\/alphastreet.com\/india\/lupin-limited-q4fy23-earnings-story\/","url_meta":{"origin":143124,"position":0},"title":"Lupin Limited Q4FY23 Earnings Story","author":"Karan_Singh","date":"May 10, 2023","format":false,"excerpt":"Lupin manufactures pharmaceuticals as a line of business. Globally, APIs, biotechnology products, and generic formulations are all developed and marketed by Lupin Limited. The firm\u00a0is a worldwide leader in the Anti-TB and Cephalosporins segments and has a substantial presence in the Cardiovascular, Diabetology, Asthma, Paediatrics, and Central Nervous system markets,\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":141240,"url":"https:\/\/alphastreet.com\/india\/lupin-ltd-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":143124,"position":1},"title":"Lupin Ltd Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"February 13, 2023","format":false,"excerpt":"Key highlights from Lupin Ltd (LUPIN) Q3 FY23 Earnings Concall Management Update: [00:03:30] LUPIN said it is optimistic of growing its US business in the next couple of years. In India, the company added close to 1,000 reps, and created 6 new divisions to expand its reach. LUPIN expects its\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":166808,"url":"https:\/\/alphastreet.com\/india\/lupin-ltd-q3fy25-39-rise-in-profits\/","url_meta":{"origin":143124,"position":2},"title":"Lupin Ltd Q3FY25; 39% rise in Profits","author":"Chirag Gupta","date":"February 12, 2025","format":false,"excerpt":"Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-7.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-7.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-7.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-7.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-7.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-7.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168697,"url":"https:\/\/alphastreet.com\/india\/lupin-ltd-q4fy25-112-rise-in-profits\/","url_meta":{"origin":143124,"position":3},"title":"Lupin Ltd Q4FY25; 112% rise in Profits","author":"Chirag Gupta","date":"June 6, 2025","format":false,"excerpt":"Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":130692,"url":"https:\/\/alphastreet.com\/india\/lupin-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":143124,"position":4},"title":"Lupin Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"June 17, 2022","format":false,"excerpt":"https:\/\/youtu.be\/KuHcJgOThAg Key highlights from Lupin Ltd (LUPIN) Q4 FY22 Earnings Concall \u00a0 Q&A Highlights: Pritesh Vora - Mission Street India - Analyst Total investment made in the biosimilar pipeline till now? Ramesh Swaminathan -- Executive Director, Global CFO A lot of LUPIN\u2019s biosimilars is under partner programs. The risk of\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":151230,"url":"https:\/\/alphastreet.com\/india\/lupin-ltd-q1fy24-29-rise-in-revenue\/","url_meta":{"origin":143124,"position":5},"title":"Lupin Ltd Q1FY24; 29% rise in Revenue","author":"Karan_Singh","date":"August 4, 2023","format":false,"excerpt":"Lupin is engaged in the business of Manufacture of Pharmaceuticals. Financial Results: Lupin Ltd reported Revenues for Q1FY24 of \u20b94,814.00 Crores up from \u20b93,744.00 Crore year on year, a rise of 28.58%. Total Expenses for Q1FY24 of \u20b94,279.00 Crores up from \u20b93,748.00 Crores year on year, a rise of 14.17%.\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-186.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-186.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-186.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-186.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-186.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-186.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/143124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1917"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=143124"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/143124\/revisions"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=143124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=143124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=143124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}